Stealth BioTherapeutics Presents Phase 2 Data From MMPOWER-2 Continuation Trial Supporting Phase 3 Development of Elamipretide in Primary Mitochondrial Myopathy

2017-06-30T08:52:39+00:00
%d bloggers like this: